




Patent Application
Attorney Docket No. PC25193A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 18th day of September, 2004.

By


(Signature of person mailing)
Janice Denison
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Jayvardhan Pandit :

APPLICATION NO.: 10/815,390 : Examiner: To be assigned

FILING DATE: 03/31/2004 : Group Art Unit: To be assigned

TITLE: Crystal Structures Of 3', 5'-Cyclic Nucleotide :
Phosphodiesterase (Pde1b) And Uses Thereof

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).


A prompt and favorable response is earnestly solicited.

Date: 9/17/04

Respectfully submitted,


Irene M. Reininger
Attorney for Applicant(s)
Reg. No. 48,439

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5756



| INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) | | | | | | | | | ATTY. DOCKET NO. PC25193A | | SERIAL NO. 10/815,390 | | | |
|--|----|-----------------|--|---|---|---|---|---|---------------------------|----------------|-----------------------|----------|-------------------------------|----|
| | | | | | | | | | APPLICANT Pandit | | | | | |
| | | | | | | | | | FILING DATE 03/31/2004 | | GROUP | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| | US | 4 | 6 | 8 | 3 | 1 | 9 | 5 | 07/28/87 | Mullis, et al. | 435/6 | 435/91 | | |
| | US | 6 | 3 | 5 | 6 | 8 | 4 | 5 | 03/12/02 | Benson, et al. | 702/19 | 435/183 | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | | |
| DOCUMENT NUMBER | | | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | | | | | | | YES | NO |
| | CA | 2 | 0 | 1 | 2 | 3 | 1 | 1 | 03/15/89 | Canada | C12N | 15/87 | | |
| | EP | 1 | 0 | 8 | 5 | 0 | 9 | 2 | 03/21/01 | Europe | C12N | 15/53 | | |
| | WO | 9 | 9 | 4 | 2 | 5 | 9 | 6 | 08/26/99 | PCT | C12N | 15/55 | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | | |
| | | | Appelt, K., <i>Crystal structures of HIV-1 protease-inhibitor complexes</i> , <u>Perspectives in Drug Discovery and Design</u> , Vol. 1: 23-48, 1993 | | | | | | | | | | | |
| | | | Beavo, J., <i>Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms</i> , <u>Physiol. Rev.</u> , Vol. 75: 725-748, 1995 | | | | | | | | | | | |
| | | | Blundell, T., et al., <i>High-throughput crystallography for lead discovery in drug design</i> , <u>Nature Reviews</u> , Vol. 11: 45-60, 2002 | | | | | | | | | | | |
| | | | Brooks, B., et al., <i>CHARMM: A program for macromolecular energy, minimization, and dynamics calculations</i> , <u>Journal of Comp. Chem.</u> , Vol. 4(2): 187-217, 1983 | | | | | | | | | | | |
| | | | Bugg, C., et al., <i>Drugs by design</i> , <u>Scientific American</u> , 93-98, 1993 | | | | | | | | | | | |
| | | | Charbonneau, H., et al., <i>Identification of a conserved domain among cyclic nucleotide phosphodiesterases from diverse species</i> , <u>Proc. Natl. Acad. Sci. (USA)</u> , Vol. 83: 9308-9312, 1986 | | | | | | | | | | | |
| | | | Cwirla, S., et al., <i>Peptides on phage: a vast library of peptides for identifying ligands</i> , <u>Proc. Natl. Acad. Sci.</u> , Vol. 87: 6378-82, 1990 | | | | | | | | | | | |
| | | | Devlin, J., et al., <i>Random peptide libraries: a source of specific protein binding molecules</i> , <u>Science</u> , Vol. 249: 404-06, 1990 | | | | | | | | | | | |
| | | | Erickson, J., <i>Design and structure of symmetry-based inhibitors of HIV-1 protease</i> , <u>Perspectives in Drug Discovery and Design</u> , Vol. 1: 109-28, 1993 | | | | | | | | | | | |
| | | | Fidock, M., et al., <i>Isolation and differential tissue distribution of two human cDNAs encoding PDE1 splice variants</i> , <u>Cellular Signalling</u> , Vol. 14: 53-60, 2002 | | | | | | | | | | | |
| | | | Francis, S., et al., <i>Zinc interactions and conserved motifs of the cGMP-binding cGMP-specific phosphodiesterase suggest that it is a zinc hydrolase</i> , <u>J. Biol. Chem.</u> , Vol. 269: 22477-22480, 1994 | | | | | | | | | | | |
| | | | Johnson, J., et al., <i>A continuous fluorescence assay for cyclic nucleotide phosphodiesterase hydrolysis of cyclic GMP</i> , <u>Analytical Biochemistry</u> , Vol. 162: 291-295, 1987 | | | | | | | | | | | |
| EXAMINER | | | | | | | | | | | | | | |
| DATE CONSIDERED | | | | | | | | | | | | | | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | | | | | | | |

| | | | | | | | | |
|--|--|--|---------------------------|---------|-----------------------|----------|-------------|----|
| INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i> | | | ATTY. DOCKET NO. PC25193A | | SERIAL NO. 10/815,390 | | | |
| | | | APPLICANT Pandit | | | | | |
| | | | FILING DATE 03/31/2004 | | GROUP | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | |
| DOCUMENT NUMBER | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | YES | NO |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | |
| | | Juarez-Martinez, G., et al., <i>High-throughput screens for postgenomics: studies of protein crystallization using Microsystems technology</i> , <i>Anal. Chem.</i> , Vol. 74: 3505-3510, 2002 | | | | | | |
| | | Kabsch, W., et al., <i>Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features</i> , <i>Biopolymers</i> , Vol. 22: 2577-2637, 1983 | | | | | | |
| | | Kissinger, C., et al., <i>Rapid automated molecular replacement by evolutionary search</i> , <i>Acta Crystallographica</i> , Vol. D55: 484-491, 1999 | | | | | | |
| | | Kruise, C., et al., <i>The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilation</i> , <i>Euro. Journal of Pharm.</i> , Vol. 420: 55-65, 2001 | | | | | | |
| | | Lam, P., et al., <i>Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors</i> , <i>Science</i> , Vol. 263: 380-84, 1994 | | | | | | |
| | | Manganiello, V., et al., <i>Perspectives in biochemistry and biophysics: diversity in cyclic nucleotide phosphodiesterase isoenzyme families</i> , <i>Archives of Biochem. and Biophys.</i> , Vol. 322(1): 1-13, 1995 | | | | | | |
| | | Meng, E., et al., <i>Automated docking with grid-based energy evaluation</i> , <i>Journal of Comp. Chem.</i> , Vol. 13(4): 505-524, 1992 | | | | | | |
| | | Morris, G., et al., <i>Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function</i> , <i>Journal of Comp. Chem.</i> , Vol. 19(14): 1639-1662, 1998 | | | | | | |
| | | Murshudov, G., et al., <i>Refinement of Macromolecular structures by the maximum-likelihood method</i> , <i>Acta Cryst.</i> , Vol. D53: 240-255, 1997 | | | | | | |
| | | Navaza, J., <i>AmoRe: an automated package for molecular replacement</i> , <i>Acta Crystallographica</i> , Vol. A50: 157-63, 1994 | | | | | | |
| | | Otwinowski, Z., et al., <i>Processing of X-Ray diffraction data collected in oscillation mode</i> , <i>Methods in Enzymology</i> , Vol. 276: 307-326, 1997 | | | | | | |
| | | Polli, J., et al., <i>Expression of a calmodulin-dependent phosphodiesterase isoforms (PDE 1B1) correlates with brain regions having extensive dopaminergic innervation</i> , <i>Journal of Neuroscience</i> , Vol. 14(3): 1251-1261, 1994 | | | | | | |
| EXAMINER | | | DATE CONSIDERED | | | | | |

| | | | | | | | | |
|---|--|---|---------------------------|---------|-------|-----------------------|-------------------------------|----|
| INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i> | | | ATTY. DOCKET NO. PC25193A | | | SERIAL NO. 10/815,390 | | |
| | | | APPLICANT Pandit | | | | | |
| | | | FILING DATE 03/31/2004 | | | GROUP | | |
| U.S. PATENT DOCUMENTS | | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | |
| DOCUMENT NUMBER | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | YES | NO |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | |
| | | Polli, J., et al., <i>Molecular cloning of DNA encoding a calmodulin-dependant phosphodiesterase enriched in striatum</i> , <u>PNAS</u> , Vol. 89: 11079-83, 1992 | | | | | | |
| | | Reed, T., et al., <i>Genomic structure and chromosome location of the murine PDE1B phosphodiesterase gene</i> , <u>Mammalian Genome</u> , Vol. 9: 571-576, 1998 | | | | | | |
| | | Scott, J., et al., <i>Searching for peptide ligands with an epitope library</i> , <u>Science</u> , Vol. 249: 386-390, 1990 | | | | | | |
| | | Smith, D., et al., <i>Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase</i> , <u>Gene</u> , Vol. 67: 31-40, 1988 | | | | | | |
| | | West, M., et al., <i>Targeting HIV-1 protease: a test of drug-design methodologies</i> , <u>TIPS</u> , Vol. 16: 67-75, 1995 | | | | | | |
| | | Wilson, J. et al., <i>Hepatocyte-directed gene transfer in vivo leads to transient improvement of hypercholesterolemia in low density lipoprotein receptor-deficient rabbits</i> , <u>Journal of Biol. Chem.</u> , vol. 267(2): 963-967, 1992 | | | | | | |
| | | Wlodawer, A., et al., <i>Structure-based inhibitors of HIV-1 protease</i> , <u>Annu. Rev. Biochem.</u> , Vol. 62: 543-585, 1993 | | | | | | |
| | | Wu, G., et al., <i>Receptor-mediated gene delivery and expression in Vivo</i> , <u>Journal of Biol. Chem.</u> , Vol. 263(29): 14621-14624, 1988 | | | | | | |
| | | Xu, R., et al., <i>Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity</i> , <u>Science</u> , Vol. 288: 1822-1825, 2000 | | | | | | |
| | | Yu, J., et al., <i>Identification and characterization of a human calmodulin-stimulated phosphodiesterase PDE1B1</i> , <u>Cell. Signal.</u> , Vol. 9(7): 519-529, 1997 | | | | | | |
| | | Zhang, K., et al., <i>A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases</i> , <u>Molecular Cell</u> , Vol. 15: 279-286, 2004 | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| DATE CONSIDERED | | | | | | | | |
| | | | | | | | | |
| <small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small> | | | | | | | | |